Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qing Xin Niu Huang Tablet (清心牛黄片) is an approved traditional Chinese medicine (TCM) developed and manufactured by Jinsheng Da Ren Tang (specifically, Tianjin Pharmaceutical Da Ren Tang Group Corp., Ltd. Lerentang Pharmaceutical Factory). Formulated to clear heart-fire, resolve phlegm, calm convulsions, and dispel wind, it contains a complex mixture of 27 herbal and animal-derived ingredients, including Calculus Bovis (人工牛黄), Cornu Bubali (水牛角浓缩粉), Realgar (雄黄), Succinum (琥珀), Borneolum Syntheticum (冰片), Radix Paeoniae Alba (白芍), and Cortex Cinnamomi (肉桂). It is primarily indicated for the treatment of symptoms associated with stroke and cerebrovascular disorders, such as mental confusion, slurred speech, excessive phlegm, dizziness, aphasia, and hemiplegia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qing Xin Niu Huang Tablet.